Clinically, both circulating and liver/tumor-infiltrating E. hirae-reactive CD8+ T cell responses were observed only in HBV-related hepatocellular carcinoma (HCC) patients but not in healthy individuals, and the frequency of these cells was positively corelated with the PFS time of the HCC patients. The gene discussed is CD8A; the disease is hepatocellular carcinoma.